Albert David Ltd.
Snapshot View

538.90 +8.25 ▲1.6%

20 May 2022, 04:01:00 PM
Volume: 251

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.albertdavidindia.com
Market Cap 307.56 Cr.
Enterprise Value(EV) 292.76 Cr. 2022-03
Financial Indicators
Earnings per share (EPS) 61.78 Trailing Twelve Months Ending 2022-03
Price-Earning Ratio (PE) 8.72 Trailing Twelve Months Ending 2022-03
Industry PE 29.26 Trailing Twelve Months Ending 2022-03
Book Value / Share 489.69 Trailing Twelve Months Ending 2022-03
Price to Book Value 1.10 Calculated using Price: 538.90
Dividend Yield 1.67 Period Ending 2021-03
No. of Shares Subscribed 0.57 Cr. 5,707,162 Shares
FaceValue 10
Company Profile

Albert David was incorporated in the year 1938. The company is a part of Kothari group.

Albert David, which has decades of illustrious presence in the health care industry, manufactures pharmaceutical formulations and bulk drugs, infusion solutions and oral solids, disposable syringes and needles and herbal formulations. The company exports these products to Vietnam, Russia, Belarus, Egypt, Bangladesh, Kenya, Tanzania, Uganda, Sudan, Ethiopia, Nigeria, Zaire, Haiti, Brazil, Canada, USA, UK, Netherlands and Germany as the company is a WHO-approved supplier.

It also has DMF for the bulk drugs, Tolbutamide and Chlorpropamide with the US Food and Drugs Administration (USFDA). The manufacturing facility for these products has been inspected and validated by the US drug regulator.

The manufacturing plants of the company are located at Ghaziabad near New Delhi, Kolkata and Mandideep near Bhopal.

The company`s amino acid range under the brand name of Alamin contains pure crystalline amino acid of high international standards manufactured under a unique technology, which conforms to WHO and FAO recommendations. In the herbal segment, the company sells its products under brand names like Adliv, which is a hepato protective and Siotone capsule, which is the only adaptogen indicated for stress.

ADL has tie-ups with Ajinomoto Co and Roussel Morishita Co of Japan for manufacturing and marketing a wide range of crystalline amino acid infusion solutions, oral solids and liquids in India.

Products offered by the Company:

The company is operating in major therapeutic segments that include:

  • Analgesics/AntiInflammatory
  • Anti-Bacterials
  •  Anti-Ulcerants
  •  Dermatologicals
  • Anxiolytics
  • Large Volume Parenteral
  •  Disposable Syringes & Needles
  • Herbal Drugs
  • Nutrition
  • Neurotropics
  •  Placental Extracts
  •  Anthelmintic
  • Haemostati
  • Cough Preparations
  • Laxatives
  • Skeletal Relaxants
  • Anti-Arthiritic / Chondroprotective Agents.

Future Plans:

  • The company will explore the possibilities for export of its IV fluids, small volume parenterals and disposable syringes in addition to its existing range.
  • It will concentrate on product line extension for its flagship brand Placentrex by bringing in newer formulations and looking for a new therapeutic area of usage.
  •  Future expansion in the herbal product range will be focused in the area of women`s healthcare.
  • ADL is planning to enter newer therapeutic areas like dermatological and ophthalmological segments.
  • Furthermore, it will also strengthen its presence in the gastrointestinal segments and in the areas of pain management.
  •  The company is also planning to launch newer products in the areas of nutritional, gynaecological and herbal medicine.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+1.55%
1 Week
+3.33%
1 Month
-9.87%
3 Month
-6.49%
6 Month
-9.78%
1 Year
+21.76%
2 Year
+9.78%
5 Year
+69.41%
10 Year
+558.00%
9 years 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) 10.93 14.67 14.96 41.80 9.98 5.33 13.44 8.85 9.48
Return on Capital Employed (%) 14.45 17.79 18.22 46.48 14.29 7.94 20.60 13.74 11.99
Return on Assets (%) 4.15 5.30 5.52 19.35 5.18 2.77 7.23 4.95 5.51

Balance Sheet View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03* Rs. Cr.
Shh. Funds 81 90 93 137 183 186 210 223 244 279
Non Curr. Liab. 42 59 14 8 9 15 20 27 26 14
Curr. Liab. 86 115 125 120 159 160 145 149 135 109
Minority Int.
Equity & Liab. 210 265 231 265 351 361 376 398 405 403
Non Curr. Assets 95 123 74 69 116 118 113 130 127 149
Curr. Assets 115 141 158 196 234 243 263 268 278 254
Misc. Exp. not W/O
Total Assets 210 265 231 265 351 361 376 398 405 403

Profit Loss View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. TTM
Net Sales 265 291 322 323 295 290 317 321 247 314
Other Income 2 1 2 2 16 10 21 7 17 16
Total Income 267 291 324 325 311 300 339 328 265 329
Total Expenditure -239 -258 -285 -291 -277 -275 -288 -290 -228 -273
PBIDT 28 33 39 33 34 25 51 38 36 57
Interest -4 -4 -3 -2 -1 -1 -1 -1 -1 -1
Depreciation -11 -11 -15 -9 -8 -8 -7 -8 -8 -9
Taxation -5 -6 -7 -15 -10 -6 -16 -10 -5 -12
Exceptional Items 41
PAT 9 13 14 48 16 10 27 19 22 35
Adjusted EPS 15 22 24 84 28 17 47 34 39 62

Cash Flow View Details

Particulars 10 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. 11 20 21 28 68 20 30 32 30 37
Cash Fr. Inv. -12 -9 -24 -9 -38 -37 -11 -19 -20 -37
Cash Fr. Finan. -11 -8 -2 -18 -18 7 -5 -17 -10 -2
Net Change -12 3 -5 1 12 -10 14 -4 0 -2
Cash & Cash Eqvt 12 15 9 10 22 -4 11 6 6 5

Shareholding Pattern View Details

9 Qtrs 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%)
Promoter 61.15 61.16 61.16 61.16 61.25 61.25 61.35 61.64 61.96
Public 38.85 38.84 38.84 38.84 38.75 38.75 38.65 38.36 38.04
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Fri, 13 May 2022
Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (Listing Regulations) we enclose herewith a copy of the Extract of the Audited Financial Results of the Company for the Quarter and Financial Year ended March 31 2022 as published in terms of Regulation 47 of the Listing Regulations in English newspaper i.e. Financial Express (all India) and vernacular newspaper (Bengali) i.e. Aajkal on May 12 2022.
Wed, 11 May 2022
Considered/Approved The Audited Financial Results For The Quarter And Financial Year Ended March 31 2022 Along With The Auditors Report (With Unmodified Opinion)
Considered/Approved the Audited Financial Results for the quarter and financial year ended March 31 2022 along with the Auditors Report (with unmodified opinion)
Wed, 11 May 2022
Board recommends Dividend
Albert David Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 11 2022 inter alia have Recommended a dividend of Rs. 9/- per equity shares of Rs. 10/- each for the financial year ended March 31 2022 subject to approval of the shareholders at the forthcoming Annual General Meeting of the Company.

Technical Scans View Details

Fri, 20 May 2022
High Delivery Percentage High Delivery Percentage
Closing Above Previous High Closing Above Previous High
High Decrease 1 Month High Decrease 1 Month
Thu, 19 May 2022
High Decrease 1 Month High Decrease 1 Month
William %R Crossed -80 From Above William %R Crossed -80 From Above

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 219,659.12 915.50 +3.5%
Divi's Laboratories Ltd. 114,020.08 4,295.05 +2.2%
Cipla Ltd. 78,954.82 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. 70,669.41 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. 52,783.35 3,671.00 +1.0%
Gland Pharma Ltd. 50,388.39 3,061.70 -1.1%
Piramal Enterprises Ltd. 45,754.22 1,917.10 +1.2%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 34.09 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-12 44.40 4,295.05 +2.2%
Cipla Ltd. Consolidated 2022-03 31.37 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 32.38 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 46.57 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2022-03 41.59 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-12 36.83 1,917.10 +1.2%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 4.25 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-12 10.53 4,295.05 +2.2%
Cipla Ltd. Consolidated 2022-03 3.79 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 3.68 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 9.54 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2022-03 7.04 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-12 1.29 1,917.10 +1.2%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 0.08 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 0.00 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 0.10 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 0.62 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 0.00 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 1.16 1,917.10 +1.2%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 14.13 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 20.97 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 1,917.10 +1.2%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 14.13 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 20.97 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 1,917.10 +1.2%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 33,498.14 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 6,969.40 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 19,159.59 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 10,560.00 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 3,462.88 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 12,809.35 1,917.10 +1.2%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 2,284.68 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 1,984.29 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 2,401.30 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 136.00 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 996.96 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 1,074.43 1,917.10 +1.2%